| 张田利,展 平,吕镗烽.肺癌靶向药物治疗新靶点和耐药特点[J].肿瘤学杂志,2020,26(9):826-832. |
| 肺癌靶向药物治疗新靶点和耐药特点 |
| New Targets and Drug Resistance in Targeted Therapy of Lung Cancer |
| 投稿时间：2019-09-04 |
| DOI：10.11735/j.issn.1671-170X.2020.09.B015 |
|
 |
| 中文关键词: 肺癌 靶向治疗 靶点 耐药 |
| 英文关键词:lung cancer targeted therapy target drug resistance |
| 基金项目:国家自然科学基金（81772500；81602015） |
|
| 摘要点击次数: 1094 |
| 全文下载次数: 223 |
| 中文摘要: |
| 摘 要：近年来肺癌的靶向治疗取得了很大的进展，多种分子驱动基因陆续被发现，如MET、Her-2、RET、KRAS、BRAF、NTRK、MEK、TROP2过表达、FGFR通路异常等。针对新靶点设计的药物层出不穷。但是患者在接受靶向治疗一段时间后往往会不可避免地出现靶向药耐药的问题。全文对肺癌靶向药物治疗中的新靶点和耐药特点作一综述。 |
| 英文摘要: |
| Abstract：Targeted therapy of lung cancer has made great progress in the past decade. Based on the discovery of novel targets such as MET，Her-2，RET，KRAS，BRAF，NTRK，MEK，TROP2 over-expression and abnormal FGFR pathway，new targeting drugs are emerging for lung cancer. But drug resistance always occurs soon after the new drug developed. The mechanisms of drug resistance includes primary resistance and secondary resistance，and re-biopsy plays an important role in discovering the mechanisms. This article summarizes the new targets in lung cancer and characteristics of drug resistance in targeted agents for lung cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |